

Molecular Therapeutics of Cancer Research Conference -- 2016

Sponsored by the Cancer Molecular Therapeutics Research Association

The University of Washington, Seattle, Washington

Schedule and Program

IMPORTANT NOTICE: By attending this conference, you agree to respect the confidentiality of the proceedings. Specifically, photographing or recording of sessions, posters or discussions is not permitted. Reference to material presented or discussed may not be included in any publication. Permission to cite information may subsequently be obtained directly from the presenter and is beyond the control of the meeting organizers.

All scientific sessions will be at Alder Hall Auditorium, 1310 NE 40th Street, Seattle, WA 98105

Breaks, Poster sessions with refreshments will be at Alder Hall

The opening reception Sunday evening will be at Alder Hall

The farewell reception will be at the Burke Museum - 4331 Memorial Way NE, Seattle 98105
(Corner of 17th Ave NE and NE 45th St.)

****Lodging will be in Lander Hall, 1201 NE Campus Parkway, Seattle, WA 98105****

Meals will be in "Local Point", located in Lander Hall

SUNDAY – JULY 17

4:00 pm	Arrival and check-in
6:00 – 7:00 pm	<i>Dinner</i>
7:30 – 7:45 pm	Welcome / Introductory Comments Peter Houghton, Greehey Children's Cancer Research Institute, San Antonio, TX, President CMTRA James Champoux, University of Washington
7:45 – 10:00 pm	EVENING SESSION: "CRISPR – Models to Drugs" Discussion Leader: Bruce Conklin, Gladstone Institute, University of California, San Francisco, CA
7:45 – 8:00 pm	Introduction
8:00 – 8:30 pm	Lukas E. Dow, Weill Cornell Medicine, New York, NY "Modeling Cancer in Vivo with CRISPR/Cas9"
8:30 – 8:55 pm	Discussion
9:00 – 9:30 pm	Jacob Corn, University of California, Berkeley "Cancer Drug Targets and Discovery Using CRISPR"
9:35 – 10:00 pm	Discussion
10:00 pm –	<i>Opening reception</i>

MONDAY – JULY 18

7:30 – 8:15 am	<i>Breakfast</i>
8:30 – 12:00 pm	MORNING SESSION: – “Immunotherapy—Beyond Checkpoints—Combinatorial Approaches/Emerging Targets” Discussion Leader: Bernard A. Fox, Oregon Health and Science University, Portland, OR
8:30 – 8:45 am	Introduction
8:45 – 9:15 am	Nils Lonberg, Bristol Myers Squibb, Redwood City, CA “Targeting CTLA-4 and PD-1 alone and in combination for cancer therapy”
9:15 – 9:40 am	Discussion
9:40 – 10:00 am	Coffee Break
10:00 – 10:30 am	Kevin Friedman, Bluebirdbio, Seattle, WA “Gene engineered T cell Technologies are Critical to Dissemination of Adoptive Cell Therapy”
10:30 – 10:55 am	Discussion
11:00 – 11:30 am	Bernard A. Fox, Oregon Health and Science University, Portland, OR “Next Generation Vaccines”
11:30 – 11:55 am	Discussion
12:00 – 1:00 pm	<i>Lunch</i>
2:00 – 4:30 pm	AFTERNOON SESSION: “Pediatric Cancers—New Advances, Lessons Learned” Discussion Leader: Peter Houghton, Greehey Children’s Cancer Research Institute, San Antonio, TX,
2:00 – 2:15 pm	Introduction
2:15 – 2:45 pm	John M. Maris, Children’s Hospital of Philadelphia, Philadelphia, PA “Targeting Neuroblastoma Clonal Evolution”
2:45 – 3:10 pm	Discussion
3:15 – 3:45 pm	A. Thomas Look, Dana-Farber Cancer Institute, Harvard University, Cambridge, MA “Molecular Pathogenesis and Drug Synergism in a Zebrafish Model of High Risk Neuroblastoma”
3:45 – 4:10 pm	Discussion
4:30 – 6:00 pm	Poster Session and Social
6:00 – 7:00 pm	<i>Dinner</i>

7:30 – 9:45 pm **EVENING SESSION: “Checkpoints—Not Just for Immunotherapy”**

Discussion Leaders: Phillip Dennis, AstraZeneca, MD

7:30 – 7:45 pm Introduction

7:45 – 8:15 pm Chris Bakkenist, University of Pittsburg, Pittsburg, PA
“ATR Signaling to Immune Checkpoints”

8:15 – 8:40 pm Discussion

8:45 – 9:15 pm David Spigel, Sarah Cannon Research Institute, Nashville, TN
“Targeting PARP: Tumor Selection and Combination Drug Development”

9:15 – 9:40 pm Discussion

9:45 pm – *Social*

TUESDAY JULY 19

7:30 – 8:15 am *Breakfast*

8:30 – 12:00 pm **MORNING SESSION: “Developing Novel Cancer Therapies – Endpoints, Combinations and Economic Considerations”**

Discussion Leader: Susan Galbraith, AstraZeneca

8:30 – 8:45 am Introduction

8:45 – 9:15 am Maria Koehler, Pfizer
“Palbociclib Development as an Insight into Endpoints for Accelerated and Full Approval for Novel Therapies in Breast Cancer”

9:15 – 9:40 am Discussion

9:40 – 10:00 am *Coffee Break*

10:00 – 10:30 am Sean Buchanan, Eli Lilly
“Abemaciclib from Bench to Bedside: The Role of Translational Research in the Development of Novel Cancer Therapies”

10:30 – 10:55 am Discussion

11:00 – 11:30 am Greg Rossi, Astrazeneca
“Cancer Drug Pricing – Can we find common ground?”

11:30 – 11:55 am Discussion

12:00 – 1:00 pm *Lunch*

1:00 – 4:30 pm **OPEN NETWORKING AFTERNOON**

4:30 – 5:45 pm **Poster Session and Social**

6:00 – 7:00 pm *Dinner*

7:30 – 9:45 pm **EVENING SESSION: “Viral Therapy for Cancer – New Approaches”**

Discussion Leader: Michael A. Barry, Mayo Clinic, Rochester, MN

7:30 – 7:45 pm Introduction

7:45 – 8:15 pm Stephen J. Russell, Mayo Clinic, Rochester, MN
“Oncolytic Viruses: Targeted Cytotoxic Drugs or Anticancer Vaccines?”

8:15 – 8:40 pm Discussion

8:45 – 9:15 pm Pedro J. Beltran, Amgen, Thousand Oaks, CA
“Talimogene Laherparepvec, From Bench to Bedside”

9:15 – 9:40 pm Discussion

9:45 pm – *Social*

WEDNESDAY JULY 20

7:30 – 8:15 am *Breakfast*

8:30 – 12:00 pm **MORNING SESSION: “How Clinical Data is Changing Drug Discovery”**

Discussion Leader: Charles “Chip” Landen, University of Virginia School of Medicine, Charlottesville, VA

8:30 – 8:45 am Introduction

8:45 – 9:15 am William S. Dalton, Moffitt Cancer Center, Tampa, FL, and ORIEN (Oncology Research Information Exchange Network)
“Accelerating Cancer Discovery and Delivery Hope through Collaborative Learning and Partnerships”

9:15 – 9:40 am Discussion

9:40 – 10:00 am Coffee Break

10:00 – 10:30 am Alice Chen, National Cancer Institute, Bethesda, MD
“NCI MATCH and Exceptional Responder Initiative”

10:30 – 10:55 am Discussion

11:00 – 11:30 am Gordon Mills, University of Texas, MD Anderson Cancer Center, Houston, TX
“Functional Genomics: Determining the Functional Consequences of Patient Mutations. What is This Teaching us About Biology and Patient Management.”

11:30 – 11:55 am Discussion

12:00 – 1:00 pm Lunch

- 2:00 – 2:55 pm **ORAL PRESENTATIONS – Four Selected Presenters from the Posters**
- 3:00 – 5:30 pm **AFTERNOON SESSION: Round Table Discussion**
“Companion Diagnostics for Personalized Medicine, Hype, Hope, or Hopeless?”
- Discussion Leader: Nicolas Dracopoli, Janssen Research and Development
Speaker/Discussant 1: Steven Averbuch, Bristol Myers Squibb
Speaker/Discussant 2: James Sun, Foundation Medicine
- 6:00 – 10:00 pm ***Farewell Reception – Burke Museum***

THURSDAY JULY 21

7:00 - 8:30 am *Breakfast*

CHECK OUT BY 11:00 AM

SPONSOR ACKNOWLEDGEMENTS

This meeting would not be possible without the generous contributions from our many friends and colleagues:

American Society for Pharmacology and Experimental Therapeutics
AbbVie
Amgen
AstraZeneca
Bristol Myers Squibb
Crown Bioscience
Genentech
Janssen Research and Development
Lilly
Pfizer

MOLECULAR THERAPEUTICS OF CANCER RESEARCH CONFERENCE 2016 – SAVE THE DATE!!

Location

PROGRAM CHAIR: TBD
JULY, 2018